Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:HRMY NASDAQ:PCVX NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$132.91$93.59$34.34▼$133.85$8.23B0.325.87 million shs3.00 million shsHRMYHarmony Biosciences$37.26$32.54$25.52▼$40.87$2.16B0.94819,657 shs1.01 million shsPCVXVaxcyte$58.39$52.21$29.08▼$65.00$8.43B1.221.91 million shs1.38 million shsQGENQiagen$40.08-0.1%$36.24$32.53▼$57.81$8.26B0.642.35 million shs1.63 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.27%+47.06%+57.59%+199.89%HRMYHarmony Biosciences0.00%+5.05%+13.05%+34.32%+16.04%PCVXVaxcyte0.00%+3.31%+19.75%+0.02%+75.50%QGENQiagen0.00%+1.83%+6.86%-2.37%-21.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$132.91$93.59$34.34▼$133.85$8.23B0.325.87 million shs3.00 million shsHRMYHarmony Biosciences$37.26$32.54$25.52▼$40.87$2.16B0.94819,657 shs1.01 million shsPCVXVaxcyte$58.39$52.21$29.08▼$65.00$8.43B1.221.91 million shs1.38 million shsQGENQiagen$40.08-0.1%$36.24$32.53▼$57.81$8.26B0.642.35 million shs1.63 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.27%+47.06%+57.59%+199.89%HRMYHarmony Biosciences0.00%+5.05%+13.05%+34.32%+16.04%PCVXVaxcyte0.00%+3.31%+19.75%+0.02%+75.50%QGENQiagen0.00%+1.83%+6.86%-2.37%-21.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.24Hold$121.25-8.77% DownsideHRMYHarmony Biosciences 2.27Hold$41.4411.23% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0047.29% UpsideQGENQiagen 2.38Hold$43.157.65% UpsideCurrent Analyst Ratings BreakdownLatest HRMY, APGE, PCVX, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026HRMYHarmony Biosciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$30.00 ➝ $36.006/25/2026QGENQiagen Kepler Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$38.606/24/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$133.00 ➝ $135.006/23/2026APGEApogee Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/23/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/23/2026APGEApogee Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/23/2026APGEApogee Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$100.00 ➝ $135.116/23/2026QGENQiagen Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOverweight$40.00 ➝ $42.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AHRMYHarmony Biosciences$868.45M2.48$3.18 per share11.72$15.11 per share2.47PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/AQGENQiagen$2.09B3.95$3.40 per share11.78$17.89 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4815.029.730.3516.20%17.19%11.99%8/4/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)QGENQiagen$424.88M$1.9120.9315.244.0019.16%14.40%8.40%8/4/2026 (Estimated)Latest HRMY, APGE, PCVX, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AQGENQiagen$0.260.65%N/A13.61%N/ALatest HRMY, APGE, PCVX, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59HRMYHarmony Biosciences0.153.583.56PCVXVaxcyteN/A7.497.49QGENQiagen0.493.212.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%HRMYHarmony Biosciences86.23%PCVXVaxcyte96.78%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%HRMYHarmony Biosciences11.00%PCVXVaxcyte3.30%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableHRMY, APGE, PCVX, and QGEN HeadlinesRecent News About These CompaniesQiagen (QGEN) Gets a Hold from Kepler CapitalJune 27, 2026 | theglobeandmail.comQiagen Acquires IngenuitySystemsJune 25, 2026 | finance.yahoo.comQiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis - SlideshowJune 24, 2026 | seekingalpha.comQiagen N.V. (QGEN) Shareholder/Analyst Call - SlideshowJune 24, 2026 | seekingalpha.comQiagen N.V. (QGEN) Shareholder/Analyst Call TranscriptJune 24, 2026 | seekingalpha.comQiagen N.V. (QGEN) Presents at JP Morgan European Healthcare Conference 2026 - SlideshowJune 18, 2026 | seekingalpha.comQiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis TranscriptJune 15, 2026 | seekingalpha.comQIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR UseJune 15, 2026 | zacks.comQIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and BiopharmaJune 15, 2026 | businesswire.comA Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75June 9, 2026 | gurufocus.comQiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?June 5, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 4, 2026 | prnewswire.comQiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENJune 2, 2026 | globenewswire.comEvaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price RecoveryJune 2, 2026 | finance.yahoo.comQiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate Conference - SlideshowJune 1, 2026 | seekingalpha.comIs QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?May 29, 2026 | zacks.comQIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus OutbreakMay 28, 2026 | businesswire.comQIAGEN Business Breakdown and Growth Drivers for 2026May 28, 2026 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 28, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, APGE, PCVX, and QGEN Company DescriptionsApogee Therapeutics NASDAQ:APGE$132.91 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$133.47 +0.56 (+0.42%) As of 07/2/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Harmony Biosciences NASDAQ:HRMY$37.26 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$35.48 -1.79 (-4.79%) As of 07/2/2026 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Vaxcyte NASDAQ:PCVX$58.39 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$58.40 +0.01 (+0.01%) As of 07/2/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Qiagen NYSE:QGEN$40.08 -0.02 (-0.05%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$39.38 -0.69 (-1.73%) As of 07/2/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
